The best next drug in the course of generalized anxiety disorders: The "pN-GAD-algorithm"

International Journal of Psychiatry in Clinical Practice

Volumn 17, Issue 2, 2013, Pages 78-89

  Linden, Michael ^a   Bandelow, Borwin ^b   Boerner, Reinhard Joachim ^c   Brasser, Matthias ^d   Kasper, Siegfried ^e   Möller, Hans Jürgen ^f   Pyrkosch, Lena ^a   Volz, Hans Peter ^g   Wittchen, Hans Ulrich ^h  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c Christian Hospital of Quakenbrück Psychiatry   (Germany)

^d PFIZER INC   (United States)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g Hospital for Psychiatry   (Germany)

^h DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Drug selection; Generalized anxiety disorder; PN algorithm; Shared decision making; Treatment algorithm

Indexed keywords

ALPRAZOLAM; AZAPERONE; BENZODIAZEPINE; BROMAZEPAM; BUSPIRONE; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; ESCITALOPRAM; FLUPENTIXOL; FLUVOXAMINE; HYDROXYZINE; IMIPRAMINE; LAVANDULA OIL; LORAZEPAM; MELPERONE; OIL; OPIPRAMOL; PAROXETINE; PLACEBO; PREGABALIN; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ALGORITHM; ANXIETY; APPETITE DISORDER; ARTICLE; ASTHENIA; ATAXIA; BLURRED VISION; CLINICAL DECISION MAKING; COORDINATION DISORDER; DIARRHEA; DIZZINESS; DROWSINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; MEMORY DISORDER; NAUSEA; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRETREATMENT NEXT TREATMENT ALGORITHM; PRIORITY JOURNAL; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SWEATING; TARDIVE DYSKINESIA; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ALGORITHMS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; CLINICAL PROTOCOLS; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 84877970514     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2012.722645     Document Type: Article

References (148)

1. Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety 2008; 25: 72-90.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
3. World Health Organization.international Statistical Classification of Diseases and Related Health Problems, 10th revision. Geneva: World Health Organization; 1992.
4. Achberger M, Linden M. Generalized anxiety disorder (GAD) in primary health care-frequencies, recognition and interventions. Psychiatr Danub 1998; 10: 373-76.
5. Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuropsychopharmacol 2005; 8: 293-302.
6. Carter RM, Wittchen HU, Pfister H, Kessler RC. One year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety 2001; 13: 78-88.
7. Kessler RC, Keller MB, Wittchen HU. The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am 2001; 24: 19-39.
8. Linden M, Maier W, Achberger M, Herr R, Helmchen H, Benkert O. Psychische Erkrankungenund ihre Behandlung in Allgemeinarztpraxen in Deutschland. Ergebnisse aus einer Studie der Weltgesundheitsorganisation (WHO). Nervenarzt 1996; 67: 205-15.
9. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Br J Psychiatry 1994; 168: 17-30.
10. Ninan PT. Recent perspectives on the diagnosis and treatment of generalized anxiety disorder. Am JManag Care 2001; 7: 367-76.
11. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 355-64.
12. Goodman WK. Selecting pharmacotherapy for generalized anxiety disorder. J Clin Psychiatry 2004; 65: 8-13.
13. Judd LL, Kessler RC, Paulus MP, Zeller PV, Wittchen HU, Kunovac JL. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand Suppl 1998; 393: 6-11.
14. Nutt D, Argyropoulos S, Hood S, Potokar J. Generalized anxiety disorder: a comorbid disease. Eur Neuropsychopharmacol 2006; 16: 109-18.
15. Carbone LA, Barsky AJ, Orav EJ, Fife A, Fricchione GL, Minden SL, Borus JF. Psychiatric symptoms and medical utilization in primary care patients. Psychosomatics 2000; 41: 512-8.
16. Greenberg PE, Sisitzky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JT, et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 1999; 66:427-35.
17. Katon W, Von Korff M, Lin E, Lipscomb P, Russo J, Wagner E, et al. Distressed high utilizers of medical care. DSMIII-R diagnosis and treatment needs. Gen Hosp Psychiatry 1990; 12: 355-62.
18. Kessler RC, DuPont RL, Berglund P, Wittchen HU. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 month in two national surveys. Am J Psychiatry 1999; 156: 1915-23.
19. Marciniak MD, Lage MJ, Dunavevich E, Russell JM, Bowman L, Landbloom RP, Levine LR. The cost of treating anxiety: the medical and demographic correlates that impact total medical costs. Depress Anxiety 2005; 21: 178-84.
20. Roy-Byrne PP, Wagner A. Primary care perspectives on generalized anxiety disorder. J Clin Psychiatry 2004; 65: 20-6.
21. Souêtre E, Lozet H, Cimarosti I, Martin P, Chignon JM, Adès J, et al. Cost of anxiety disorders: impact of comorbidity. J Psychosom Res 1994; 38: 151-60.
22. Wagner R, Silove D, Marnane C, Rouen D. Delays in referral of patients with social phobia, panic disorder and generalized anxiety disorder attending a specialist anxiety clinic. JAnxiety Disord 2006; 20: 363-71.
23. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002; 16: 162-71.
24. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Borkovec TD, Rickels K, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001; 62: 53-8.
25. Yonkers KA, Warshaw MG, Massion AO, Keller MB. Phenomenology and course of generalized anxiety disorder. Br J Psychiatry 1996; 168: 308-13.
26. Davidson J.R. Generalized anxiety and panic: common, costly, and challenging disorders and their pharmacologic management. CNS Spectr 2004; 9: 1-7.
27. Mitte K. Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy. Psychol Bull 2005; 131: 785-95.
28. Rynn MA, Brawman-Mintzer O. Generalized anxiety disorder: acute and chronic treatment. CNS Spectr 2004; 9: 716-23.
29. L, Vermani M, Coonerty-Femiano A, Katzman MA. Treatments for generalized anxiety disorder. Expert Rev Neurother 2004; 4: 285-94.
30. Ninan PT. New insights into the diagnosis and pharmacologic management of generalized anxiety disorder. Psychopharmacol Bull 2002; 36: 105-22.
31. Baldwin DS, AndersoniM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19: 567-96.
32. Bielski RJ, Bose A, Chang CC. Adouble-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005; 17: 65-9.
33. Bose A, Korotzer A, Gommoll C, LiD. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depress Anxiety 2008; 25: 854-61.
34. Davidson J R, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: doubleblind, placebo controlled, fl exible-dose study. Depress Anxiety 2004; 19: 234-40.
35. Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. JAffect Disord 2005; 87: 161-7.
36. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, fl exible-dosage trial. J Clin Psychiatry 2001; 62: 350-57.
37. Rickels K, Zaninelli R, McCafferty J, Bellew K,iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160: 749-56.
38. Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997; 95: 444-50.
39. Stocchi F, Nordera G, Jokinen R, Lepola UM, Hewett K, Bryson H, et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 2003; 64: 250-8.
40. Allgulander C, Cloninger CR, Przybeck TR, Brandt L. Changes on the Temperament and Character Inventory after paroxetine treatment in volunteers with generalized anxiety disorder. Psychopharmacol Bull 1998; 34: 165-6.
41. Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels K. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006; 67: 874-81.
42. RUPPASG (Research Unit on Pediatric Psychopharmacology Anxiety Study Group). Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 2001; 344: 1279-85.
43. Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001; 158: 2008-14.
44. Varia I, Rauscher F. Treatment of generalized anxiety disorder with citalopram. Int Clin Psychopharmacol 2002; 17: 103-7.
45. Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003; 42: 415-23.
46. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ. WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive compulsive and posttraumatic stress disorders-first revision. World J Biol Psychiatry 2008; 9: 248-312.
47. Gorman JM. Treatment of generalized anxiety disorder. J Clin Psychiatry 2002; 63: 17-23.
48. Price JS, Waller PC, Wood SM, MacKay AV. Acomparison of the post-marketing safety of four selective serotonin reuptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42: 757-63.
49. Stahl MM, Lindquist M, Pettersson M, Edwards IR, Sanderson JH, Taylor NF, et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997; 53: 163-9.
50. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalized anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001; 179: 15-22.
51. Davidson JR, DuPont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999; 60528-35.
52. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 2000; 283: 3082-88.
53. Katz Ir, Reynolds CF III, Alexopoulos GS, Hackett D. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc 2002; 50: 18-25.
54. Montgomery SA, Sheehan DV, Meoni P, Haudiquet V, Hackett D. Characterization of the longitudinal course of improvement in generalized anxiety disorder during longterm treatment with venlafaxine XR. J Psychiatr Res. 2002; 36: 209-17.
55. Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000; 157: 968-74.
56. Kasper S, Blagden M, Seghers S, Veerman A, Volz HP, Geniaux A, et al. Aplacebo-controlled study of pregabalin and venlafaxine treatment of GAD. Poster, Congress of the American Psychiatric Association (APA); 2002.
57. Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel F, et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-Week trial. Int Clin Psychopharmacol 2009; 24: 87-96.
58. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006; 67: 771-82.
59. Boyer P, Mahé V, Hackett D. Social adjustment in generalised anxiety disorder: a long-term placebo-controlled study of venlafaxine extended release. Eur Psychiatry 2004; 19: 272-9.
60. Koponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Detke MJ, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 2007; 9: 100-7.
61. Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a fl exible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2008; 25: 182-9.
62. Allgulander C, Nutt D, Detke M, Erickson J, Spann M, Walker D, et al. Anon-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J Psychopharmacol 2008; 22: 417-25.
63. Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007; 22: 167-74.
64. Nicolini H, Bakish D, Duenas H, Spann M, Erickson J, Hallberg C, et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extendedrelease and placebo-controlled trial. Psychol Med 2009; 39: 267-76.
65. Davidson JR, Wittchen HU, Llorca PM, Erickson J, Detke M, Ball SG, Russell JM. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2008; 18: 673-81.
66. Schmitt R, Kratz Gazalle F, Silva de Lima M, Cunha A, Souza J, Kapczinski F. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and metaanalysis. Rev Bras Psiquiatr 2005; 27: 18-24.
67. Sheehan DV. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. J Clin Psychiatry 1999; 60: 23-28.
68. Pande AC, Crockatt J G, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003; 160: 533-40.
69. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005; 62(9): 1022-30.
70. Möller HJ, Brasser M, Kasper S, Volz HP, Boerner RJ, Bandelow B. Wirksamkeit und Verträglichkeit von Pregabalin bei Patienten mit generalisierten Angstst örungen in der täglichen Praxis. Psychopharmakotherapie 2009; 16: 211-7.
71. Aliyev NA, Aliyev ZN. Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study. Eur Psychiatry 2008; 23: 109-14.
72. Cohn JB, Bowden CL, Fisher JG, Rodos JJ. Double-blind comparison of buspirone and clorazepate in anxious outpatients. Am J Med 1986; 80: 10-6.
73. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 1988; 49: 293-301.
74. Kahn RJ, McNair DM, Lipman RS, Covi L, Rickels K, Downing R, et al. Imipramine and chlordiazepoxide in depressive and anxiety disorders. II: efficacy in anxious outpatients. Arch Gen Psychiatry 1986; 43: 79-85.
75. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50: 884-95.
76. Möller HJ, Volz HP, ReimanniW, Stoll KD. Opipramol for the treatment of generalized anxiety disorder: a placebocontrolled trial including an alprazolam-treated group. J Clin Psychopharmacol 2001; 21: 59-65.
77. Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2002; 63: 9-16.
78. Martin J LR, Sainz-Pardo M, Furukawa TA, Martin-Sanchez E, Seoane T, Galan C. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol 2007; 21: 774-82.
79. Boyer WF, Feighner JP. Aplacebo-controlled double-blind multicenter trial of two doses of ipsapirone versus diazepam in generalised anxiety disorder. Int Clin Psychopharmacol 1993; 8: 173-6.
80. Cohn JB, Wilcox CS. Long-term comparison of alprazolam, lorazepam and placebo in patients with anxiety disorder. Pharmacotherapy 1984; 4: 93-8.
81. Elie R, Lamontagne Y. Alprazolam and diazepam in the treatment of generalized anxiety. J Clin Psychopharmacol 1984; 4: 125-9.
82. Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacolog 1991; 105: 428-32.
83. Feighner JP, Merideth CH, Hendrickson GA. Adoubleblind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry 1982; 43: 103-8.
84. Figueira ML. Alprazolam SR in the treatment of generalized anxiety: a multicentre controlled study with bromazepam. Hum Psychopharmacol Clin Exp 1999; 14: 171-7.
85. Fontaine R, Annable L, Chouinard G, Ogilvie RI. Bromazepam and diazepam in generalised anxiety: a placebo-controlled study with measurement of drug plasma concentrations. J Clin Psychopharmacol 1983; 3: 80-7.
86. Jacobson AF, Dominguez RA, Goldstein BJ, Steinbook RM. Comparison of buspirone and diazepam in generalized anxiety disorder. Pharmacotherapy 1985; 5: 290-6.
87. Laakmann G, Schule C, Lorkowski G, Baghai T, Kuhn K, Ehrentraut S. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology 1998; 136: 357-66.
88. Linden M, Pyrkosch L. How to review the medication history to find the next best drug: the "Pretreatment -Next Treatment Algorithm and Checklist". Current Psychopharmacology 2012; 1: 61-6.
89. Lydiard RB, Ballenger J C, Rickels K. Adouble-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil work group. J Clin Psychiatry 1997; 58: 11-8.
90. Power KG, Simpson RJ, Swanson V, Wallace LA, Feistner ATC, Sharp DA. Acontrolled comparison of cognitive-behaviour therapy, diazepam and placebo alone and in combination for the treatment of generalized anxiety disorder. JAnxiety Disord 1990; 4: 267-92.
91. Rickels K, Case WG, Downing RW, Winokur A. Long-term diazepam therapy and clinical outcome. JAMA 1983; 250: 767-71.
92. Rickels K, FoxiL, Greenblatt DJ, Sandler KR, Schless A. Clorazepate and lorazepam: clinical improvement and rebound anxiety. Am J Psychiatry 1988; 145: 312-7.
93. Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H. Long-term treatment of anxiety and risk of withdrawal: prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988; 45: 444-50.
94. Schweizer E, DeMartinis N, Mandos L, Mercer C. Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychopharmacol 1997; 17: 272-7.
95. Rickels K, DeMartinis N, Aufdembrinke B. Adoubleblind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder. J Clin Psychopharmacol 2000; 20: 12-8.
96. Ross CA, Matas M. Aclinical trial of buspirone and diazepam in the treatment of generalised anxiety disorder. Can J Psychiatry 1987; 32: 351-5.
97. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993; 328: 1398-405.
98. Möller HJ, Volz HP, ReimanniW, Stoll KD. Opipramol for the treatment of generalized anxiety disorder: a placebocontrolled trial including an alprazolam-treated group. J Clin Psychopharmacol 2001; 21: 59-65.
99. Ansseau M, Olie JP, von Frenckell R, Jourdain G, Stehle B, Guillet P. Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder. Psychopharmacology 1991; 104: 439-43.
100. Feltner DE, Crockatt J G, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. Arandomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240-9.
101. Llorca PM, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E, et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3 months double blind study. J Clin Psychiatry 2002; 63: 1020-7.
102. Pourmotabbed T, McLeod DR, Hoehn-Saric R, Hipsley P, Greenblatt DJ. Treatment, discontinuation, and psychomotor effects of diazepam in women with generalized anxiety disorder. J Clin Psychopharmacol 1996; 16: 202-7.
103. Rickels K, Weisman K, Norstad N, Singer M, Stoltz D, Brown A, Danton J. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982; 43: 81-6.
104. Aufdembrinke B. Abecarnil, a new beta-carboline, in the treatment of anxiety disorders. Br J Psychiatry Suppl 1998; 34: 55-63.
105. De Jonghe F, Swinkels J, Tuynman-Qua H, Jonkers F. Acomparative study of suriclone, lorazepam and placebo in anxiety disorder. Pharmacopsychiatry 1989; 22: 266-71.
106. Pollack MH, Worthington J J, Manfro GG, Otto MW, Zucker BG. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry 1997; 58: 19-23.
107. Livingston MG. Benzodiazepine dependence. Br J Hosp Med 1994; 51: 281-6.
108. Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol 1999; 6: 69-83.
109. Rickels K, Schweizer E, Case WG, Greenblatt DJ. Longterm therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry 1990; 47: 899-907.
110. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Longterm therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry 1990; 47: 908-915.
111. Smith DE, Landry MJ. Benzodiazepine dependency discontinuation: focus on the chemical dependency detoxifi-cation setting and benzodiazepine-polydrug abuse. J Psychiatr Res 1990; 24: 145-56.
112. Woods J H, Katz J L, Winger G. Benzodiazepines: unse, abuse, and consequences. Pharmacol Rev 1992; 44: 151-347.
113. American Psychiatric Association Task Force on Benzodiazepine Dependency, editor. Benzodiazepine dependence, toxicity, and abuse: a task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1990.
114. Ansseau M, Papart P, Gérard MA, von Frenckell R, Franck G. Controlled comparison of buspirone and oxazepam in generalized anxiety. Neuropsychobiology 1990-1991; 24: 74-8.
115. Bourin M, Malinge M. Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 567-75.
116. Feighner J P. Buspirone in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 1987; 48: 3-6.
117. Feighner J P, Cohn J B. Analysis of individual symptoms in generalized anxiety-a pooled, multistudy, double-blind evaluation of buspirone. Neuropsychobiology 1989; 21: 124-30.
118. Murphy SM, Owen R, Tyrer P. Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks treatment with diazepam or buspirone. Br J Psychiatry 1989; 154: 529-34.
119. Olajide D, Lader M. Acomparison of buspirone, diazepam, and placebo in patients with chronic anxiety states. J Clin Psychopharmacol 1987; 7: 148-52.
120. Pecknold JC, Matas M, Howarth BG, Ross C, Swinson R, Vezeau C, Ungar W. Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo. Can J Psychiatry 1989; 34: 766-71.
121. Rakel RE. Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. South Med J 1990; 83: 195-8.
122. Sramek JJ, Frackiewicz EJ, Cutler NR. Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety. Clin Ther 1997; 19: 498-506.
123. Strand M, Hetta J, Rosen A, Sör ensen S, Malmstr öm R, Fabian C, et al. Adouble-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry 1990; 51: 40-5.
124. Gammans RE, Stringfellow J C, Hvizdos AJ, Seidehamel RJ, Cohn JB, Wilcox CS, et al. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. Ameta-analysis of eight randomized, controlled studies. Neuropsychobiology 1992; 25: 193-201.
125. Lader M, Scotto JC. Amulticentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology 1998; 139: 402-6.
126. Wittchen HU, Kessler RC, Beesdo K, Krause P, Höfler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition and management. J Clin Psychiatry 2002; 63: 24-34.
127. Newton RE, Marunycz J D, Alderdice MT, Napoliello MJ. Review of the side-effect profile of buspirone. Am J Med 1986; 80: 17-21.
128. Taylor DP. Serotonin agents in anxiety. Ann NY Acad Sci 1990; 600: 545-57.
129. Ferreri M, Hantouche EG, Billardon M.interêt de l'hydroxyzine dans le trouble anxiétégéneralisée:étude contrôle en double aveugle versus placebo. Encephale 1994; 20: 785-91.
130. Ferreri M, Hantouche EG. Recent clinical trials of hydroxyzine in generalized anxiety disorder. Acta Psychiatr Scand Suppl 1998; 393: 102-8.
131. Mendels J, Krajewski TF, Huffer V, Taylor RJ, Secunda S, Schless A, et al. Effective short-term treatment of generalized anxiety with trifl uoperazine. J Clin Psychiatry 1986; 47: 170-4.
132. Brawman-Mintzer O, Knapp R, Nietert P. Placebo controlled study of Risperidone augmentation in treatment resistent subjects with DSM-IV diagnosis of GAD. Poster, annual meeting of the European College of Neuropsychopharmacolog y; 2003.
133. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2005; 66: 1321-5.
134. Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 2006; 59: 211-5.
135. Lohoff FW, Etemad B, Mandos LA, Gallop R, Rickels K. Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. J Clin Psychopharmacol 2010; 30: 185-9.
136. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo-and active-controlled study. Int J Neuropsychopharmacol 2010; 13: 305-20.
137. Merideth C, Cutler AJ, She F, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol 2012; 27: 40-54.
138. Kasper S, Gastpar M, Müller WE, Volz HP, Möller HJ, Dienel A, Schläfke S. Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal'anxiety disorder-a randomised, doubleblind, placebo controlled trial. Int Clin Psychopharmacol 2010; 25: 277-87.
139. Müller WE, Volz HP, Möller HJ, Dienel A, Schläfke S. Efficacy and safety of silexan, a new orally administered lavender oil preparation, in subthreshold anxiety disorder-evidence from clinical trials. Wien Med Wochenschr 2010; 160: 547-56.
140. Woelk H, Arnoldt KH, Kieser M, Hoerr R. Ginkgo biloba special extract Egb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res 2007; 41: 472-80.
141. Bonne O, Shemer Y, Gorali Y, Katz M, Shalev AY. Arandomized, double-blind, placebo-controlled study of classical homeopathy in generalized anxiety disorder. J Clin Psychiatry 2003; 64: 282-7.
142. Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Okasha A, et al. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr 2003; 8: 53-61.
143. Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 2006; 51: 9S-91S.
144. National Institute for Health and Clinical Excellence (NICE). Anxiety (amended): Management of Anxiety (Panic Disorder, with or without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care; 2011.
145. Hidalgo RB, Tupler LA, Davidson JRT. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 2007; 21: 864-72.
146. Rote Liste Service GmbH. Rote Liste 2 003. Aulendorf: Editio Cantor Verlag; 2003.
147. Hamman J, Leucht S, Kissling W. Shared decision making in psychiatry. Acta Psychiatr Scand 2003; 107: 403-9.
148. Reichhart T, Kissling W, Scheuring E, Hamann J. Patient participation in German psychiatry -a critical review. Psychiat Prax 2008; 35: 111-21.